Recombinant human G-CSF protein - Bioactive cytokine

Recombinant cytokine, source: E. coli

SPECIFICATIONS

Specifications

Source
E. coli
Species
Human
Synonyms
Colony-stimulating factor 3
CSF3
Accession sequence

P09919-2

Molecular weight
18 kDa (SDS-PAGE)
Carrier
Carrier-free
Tag
Tag-free
Purity
≥95% (SDS-PAGE)
Solubility

100 μg/ml in water

Formulation buffer

HAc-NaAc, 150 mM NaCl, 0.004 % Tween 80.5 % Mannitol, pH 4.0

Appearance (form)
Lyophilized
Reconstitution buffer
1X PBS with 0.1 % BSA or HSA (not provided)
Endotoxin

The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.

Tested applications

Cellular assays

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Recombinant human G-CSF
  • Cat code: 
    rcyec-hgcsf
  • Quantity: 
    10 µg

Shipping & Storage

  • Shipping method:  Room temperature
  • Storage:

    • -20 °C

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

The granulocyte colony-stimulating factor (G-CSF) is a secreted cytokine and hematopoietic growth factor that belongs to the Type I/II cytokine receptor family. G-CSF regulates the differentiation, proliferation, and function of neutrophils [1]. It exerts its biological functions through the formation of a tetramer consisting of two G-CSF molecules and the homodimeric G-CSF receptor (GCSFR, aka CD114). The binding of G-CSF to its receptor triggers activation of the JAK/STAT signaling pathway [1,2]. STAT1, STAT3, and STAT5 are involved in this activation step and the induction of cellular proliferation [1,2]. 

Due to its well-known function in the maturation and mobilization of neutrophils from the bone marrow, it is widely used as an adjuvant treatment in severe cases of chemotherapy-induced neutropenia during hematopoietic stem cell transplantation in multiple myeloma treatment [3-4]. Studies in humans and mice also indicate that while G-CSF contributes to host defense against pathogens, it can also have detrimental effects by promoting inflammatory diseases and cancer [1,2,4]. A plethora of studies have shown that G-CSF-secreting tumors are highly aggressive and directly linked with secondary metastasis, worse prognosis, and low survival rates [4]. However, other studies have suggested that within the G-CSF-secreting tumor, the dynamic changes caused in the tumor microenvironment can be used as markers of early disease progression and therapeutic response [4]. 

 

​References:

1. Martin KR., et al., 2021. G-CSF — A double-edged sword in neutrophil-mediated immunity. Sem Immunol. 54:101516.
2. Park, DS., et al., 2022. A review of granulocyte colony-stimulating factor receptor signaling and regulation with implications for cancer. Front Oncol. DOI: 10.3389/fonc.2022.932608.
3. Crees ZD, et al., 2023. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med. 29(4):869-879.
4. Karagiannidis I, et al. 2021. G-CSF in tumors: Aggressiveness, tumor microenvironment and immune cell regulation. Cytokine. 142:155479.

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?